Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HOTH 
Hoth Therapeutics Inc (HOTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: HOTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.32% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.21M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 2 | Beta 0.68 | 52 Weeks Range 0.65 - 2.79 | Updated Date 09/15/2025 |
52 Weeks Range 0.65 - 2.79 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.11% | Return on Equity (TTM) -104.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12221661 | Price to Sales(TTM) - |
Enterprise Value 12221661 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 13259000 | Shares Floating 12705463 |
Shares Outstanding 13259000 | Shares Floating 12705463 | ||
Percent Insiders 4.18 | Percent Institutions 2 |
Upturn AI SWOT
Hoth Therapeutics Inc
Company Overview
History and Background
Hoth Therapeutics, Inc. is a biopharmaceutical company focused on developing new therapies for unmet medical needs. Founded in 2017, they focus on indications including atopic dermatitis, also known as eczema, as well as other dermatological conditions. Recent efforts include developments for treating PTSD and Lupus.
Core Business Areas
- Dermatology: Focuses on developing therapies for skin conditions, primarily atopic dermatitis (eczema). Their lead product candidate targets this condition.
- Dermatological and Autoimmune Indications: Expands research and development efforts into treatments for conditions such as PTSD and Lupus, using advanced methods to address unmet medical needs in those areas.
Leadership and Structure
The leadership team consists of experienced professionals in the biopharmaceutical industry, with expertise in drug development, regulatory affairs, and commercialization. The organizational structure is typical of a small biotech firm, with research, development, and administrative functions.
Top Products and Market Share
Key Offerings
- HT-001: HT-001 is the lead product candidate focused on treating atopic dermatitis. Market share is currently 0% as the product is still in development. Competitors include companies developing topical corticosteroids, calcineurin inhibitors, and biologics (e.g., Sanofi/Regeneron's Dupixent).
- BioLexa Platform: A new development to treat Lupus. No current market share exists as the drug is in initial stages. Competitors would include existing Lupus medication.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Market dynamics are driven by innovation, patent protection, and the prevalence of specific diseases.
Positioning
Hoth Therapeutics is a small player in the biopharmaceutical industry, focusing on niche markets with unmet medical needs. Their competitive advantage lies in their innovative approach to drug development and their focus on specific dermatological conditions and expanding to autoimmune indications.
Total Addressable Market (TAM)
The global atopic dermatitis market is estimated to be worth billions of dollars. Hoth Therapeutics' positioning depends on successful clinical trials and regulatory approval. TAM for Lupus and PTSD is also substantial.
Upturn SWOT Analysis
Strengths
- Innovative drug development platform
- Focus on unmet medical needs
- Experienced leadership team
- Intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Lack of commercial infrastructure
- Small size compared to major pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Regulatory approvals
- Government grants and funding
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
- Patent expirations
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- SNY (Sanofi)
- REGN (Regeneron)
- LLY (Eli Lilly and Company)
Competitive Landscape
Hoth Therapeutics faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Their competitive advantage lies in their niche focus and innovative drug development platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the expansion of the company's pipeline and preclinical and clinical development activities.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its product candidates. Analyst estimates vary widely due to the inherent risks in the biotech industry.
Recent Initiatives: Recent initiatives include advancing HT-001 through clinical trials, expanding research into PTSD and Lupus, and securing partnerships.
Summary
Hoth Therapeutics is a high-risk, high-reward biopharmaceutical company focused on developing therapies for unmet medical needs. Success depends on positive clinical trial results and regulatory approvals, which carry significant uncertainty. The company's limited financial resources and competition from established players pose challenges, while successful development of its pipeline could lead to substantial growth. Monitoring clinical progress and financial stability is crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotech industry is inherently risky, and results are not guaranteed. Data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hoth Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-02-15 | Founder, President, CEO & Chairman Mr. Robb Knie | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://hoththerapeutics.com |
Full time employees 2 | Website https://hoththerapeutics.com | ||
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.